Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).
Nicholas David James
Consultant or Advisory Role - Novartis; Sanofi
Honoraria - Novartis; Sanofi
Research Funding - Novartis; Sanofi
Sarah Pirrie
No relevant relationships to disclose
Darren Barton
No relevant relationships to disclose
Janet Elizabeth Brown
Consultant or Advisory Role - Amgen (U); Bristol-Myers Squibb (U); Novartis (U)
Honoraria - Amgen; Novartis
Research Funding - Novartis
Lucinda Billingham
No relevant relationships to disclose
Stuart I. Collins
No relevant relationships to disclose
Adam Daunton
No relevant relationships to disclose
Alison J. Birtle
No relevant relationships to disclose
Prabir Ranjan Chakraborti
No relevant relationships to disclose
Daniel Ford
Consultant or Advisory Role - Sanofi (U)
Honoraria - Sanofi
Research Funding - Sanofi
Syed A. Hussain
No relevant relationships to disclose
Helen Jones
No relevant relationships to disclose
Ann Pope
No relevant relationships to disclose
Emilio Porfiri
Consultant or Advisory Role - Astellas Pharma; Johnson & Johnson
Honoraria - Sanofi
John Martin Russell
No relevant relationships to disclose
Andrew Stanley
No relevant relationships to disclose
John Staffurth
No relevant relationships to disclose
Duncan McLaren
No relevant relationships to disclose
Chris Parker
No relevant relationships to disclose
James Wylie
No relevant relationships to disclose